Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study.
Durez P, Van den Bosch F, Corluy L, Veys EM, De Clerck L, Peretz A, Malaise M, Devogelaer JP, Vastesaeger N, Geldhof A, Westhovens R. Durez P, et al. Among authors: geldhof a. Rheumatology (Oxford). 2005 Apr;44(4):465-8. doi: 10.1093/rheumatology/keh494. Epub 2005 Feb 3. Rheumatology (Oxford). 2005. PMID: 15695306
DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment.
Vander Cruyssen B, Van Looy S, Wyns B, Westhovens R, Durez P, Van den Bosch F, Veys EM, Mielants H, De Clerck L, Peretz A, Malaise M, Verbruggen L, Vastesaeger N, Geldhof A, Boullart L, De Keyser F. Vander Cruyssen B, et al. Among authors: geldhof a. Arthritis Res Ther. 2005;7(5):R1063-71. doi: 10.1186/ar1787. Epub 2005 Jul 8. Arthritis Res Ther. 2005. PMID: 16207323 Free PMC article.
Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity.
Vander Cruyssen B, Van Looy S, Wyns B, Westhovens R, Durez P, Van den Bosch F, Mielants H, De Clerck L, Peretz A, Malaise M, Verbruggen L, Vastesaeger N, Geldhof A, Boullart L, De Keyser F. Vander Cruyssen B, et al. Among authors: geldhof a. Arthritis Res Ther. 2006;8(4):R112. doi: 10.1186/ar2001. Arthritis Res Ther. 2006. PMID: 16978395 Free PMC article.
39 results